Background SLE is a complex autoimmune condition requiring evaluation across disease activity, permanent damage and ...

Objective Systemic lupus erythematosus Prospective Observational Cohort Study (SPOCS) was a prospective observational study ...

Fertility is often a concern for women with SLE. In addition to known indirect factors that influence the ability of a woman with SLE to become pregnant, such as cytotoxic agents, other medications, ...

Objectives Dysregulated IRF5 activity drives type I interferon, pathogenic cytokine production, and B cell activation and differentiation downstream of TLR7/8/9 signaling, contributing to systemic ...

Objective To assess the effectiveness of belimumab (BEL) in improving anaemia, thrombocytopenia, lymphopenia and leucopenia in patients with SLE. Conclusion In this real-world cohort, BEL treatment ...

Objective Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterised by venous thrombosis (VT) or arterial thrombosis (AT) and/or pregnancy morbidity and the presence of ...

Objective Corticosteroids are a mainstay of SLE treatment; however, cumulative steroid exposure may lead to organ damage. This study aimed to quantify the risk of new diabetes, hypertension, cataracts ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to ...

Objective Systemic lupus erythematosus (SLE) is associated with increased risk for adverse pregnancy outcomes (APOs). The Predictors of Pregnancy Outcomes: Biomarkers in Antiphospholipid Syndrome and ...

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...